Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.65 |
| ▸ | SRC | P12931 | 5/20 | 0.65 |
| ▸ | HCK | P08631 | 4/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
| ▸ | BTK | Q06187 | 19/20 | 0.63 |
| ▸ | LCK | P06239 | 9/20 | 0.63 |
| ▸ | ITK | Q08881 | 6/20 | 0.63 |
| ▸ | JAK3 | P52333 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 6/20 | 0.61 |
| ▸ | LYN | P07948 | 5/20 | 0.61 |
| ▸ | FLT3 | P36888 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860354 | 1.00 | EGFR (0.65) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL13861274 | 0.90 | SRC (0.61) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL13861407 | 0.89 | FYN (0.64) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL15517441 | 0.89 | SRC (0.63) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL13860192 | 0.88 | SRC (0.60) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL15934560 | 0.87 | BTK (0.59) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL13860328 | 0.87 | BTK (0.67) | BTK | |
| SCHEMBL5805094 | 0.85 | ABL1 (0.73) | EGFRSRCHCKPIK3CDABL1 | |
| Trifluoroacetic Acid SCHEMBL15517610 | 0.83 | BTK (0.58) | EGFRSRCHCKPIK3CDABL1 | |
| SCHEMBL15516278 | 0.81 | LCK (0.63) | EGFRSRCHCKKDRMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2012158795-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | EGFR 45/4885SRC 25/4885HCK 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.